Positivity of pSIRT6 expression predicted an 18.649-fold (95% CI; 1.949–178.412) greater risk in OS analysis, and CSNK2A1 expression predicted a 10.374–fold (95% CI; 2.244–47.968) greater risk in RFS analysis in osteosarcoma patients who received adjuvant chemotherapy (Table 4). The gene discussed is CSNK2A1; the disease is osteosarcoma.